Alkem Laboratories has announced the appointment of Mr. Chanakya Misra to a senior management position within the company, effective 18 May 2026. The disclosure was made pursuant to Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and was communicated to both BSE Limited and the National Stock Exchange of India Limited.

Appointment Details

The following table summarises the key details of the appointment as disclosed by the company:

Professional Profile

Mr. Chanakya Misra holds an MBA in Marketing & International Business and a Bachelor of Pharmacy from IIT (BHU). He brings with him over 25 years of professional experience spanning pharmaceuticals, public health, rare diseases, and healthcare ecosystems.

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 read with Schedule III, Part A of the SEBI LODR Regulations, as well as the SEBI Master Circular bearing reference HO/49/14/14(7)2025-CFDDPOD2/1/3762/2026 dated January 30, 2026. The filing was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer of Alkem Laboratories. The information has also been made available on the company's official website.

Alkem Laboratories has informed the stock exchanges that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection at the company's Contract Research Organisation (CRO) facility located in Taloja, Maharashtra, on May 8, 2026. The inspection concluded without the issuance of a Form 483, signalling a clean outcome for the facility.

US FDA Inspection at Taloja CRO Facility

The unannounced inspection was carried out by the US FDA on May 8, 2026, at Alkem Laboratories' CRO facility in Taloja, Maharashtra. A Form 483 is issued by the US FDA when investigators observe conditions that may constitute violations of regulations during an inspection. The absence of a Form 483 at the conclusion of this inspection indicates that no objectionable conditions or regulatory violations were noted by the inspecting authority.

Key details of the inspection are summarised below:

Regulatory Disclosure

The disclosure was made to both BSE Limited and the National Stock Exchange of India Limited in compliance with applicable listing regulations. The communication was signed by Manish Narang, President – Legal, Company Secretary and Compliance Officer of Alkem Laboratories Limited, confirming the outcome of the inspection on the same day it was conducted.